Global Antibody Drug Conjugates Market: Analysis, Trends, and Forecast

Antibody Drug Conjugates are another category of profoundly powerful natural medications manufactured by attaching a small molecule of anticancer drug or another therapeutic drug to an antibody with either permanent or liable linker. The immunizer focuses on a particular antigen just found on target cells.

Unlike chemotherapy, Antibody Drug Conjugates (ADC’s) are purposefully designed in a way to target and kill tumor cells while sparing the healthy ones. Antibody Drug Conjugate consists of a highly discriminating monoclonal antibody for a cancer related antigen that has limited or no articulation on normal healthy cells. A linker that is steadily available for use, yet delivers the cytotoxic specialist in target cells.Antibody drug conjugates are comprised of three segments as a target specific antibody antigen, restricted expression on normal cell antigen, a cytotoxic agent designed to kill the primary cancer cell, and a chemical linker to attach cytotoxic agent to the antibody. Antibody drug conjugates have the therapeutic ability and possess both technological and developmental challenges. The antibody conjugates are considered to be ultramodern healing agent. They combine the targeting capacity of monoclonal antibody and aim specific cell killing ability of cytotoxic drugs.

Antibody Drug Conjugates Market: Overview

The Antibody Drug Conjugates Market is appreciated to demonstrate a substantial upswing of a CAGR of 12.9% during the forecasted period of 2023 to 2030. The Market is set to be valued at USD 3,198 billion in 2023 and is estimated to display a significant improvement of USD 7475.74 billion by 2030.Due to the advancement in technology the antibody conjugates market is achieving success in the global market. Antibody drug market is novel and profoundly powerful natural medication that is receiving attention from both large and small scale pharmaceuticals industries.

The potency of the cytotoxic medicine in an antibody drug is 100 to 1000 times more than the cytotoxic drug when it acts alone. Antibody drug conjugates are usually used for in cancer treatment and to help increase cell killing monoclonal antibodies. ADC’s consist many advantages such as high tumour sensitivity, restricted systematic exposure, and increased drug tolerability. Rising preclinical research programs, growing number of clinical trials with regards to cancer therapeutics, rising emphasis of pharmaceutical companies for new drug research and discovery and evolution of advanced therapies are some factors that are accelerating the growth.

Antibody Drug Conjugates Market: Key Trends

Unhealthy lifestyle of people twining with rise in tobacco consumption is boosting the market.
Due to unhealthy lifestyle of people across the globe there is steep rise in prevalence of cancer and cancerous diseases. Additionally, surge in tobacco consumption through geographies posing the risk of cancer. As per the report by National Cancer Institute, the number of people existing beyond diagnosis is expected to extend up to 19 million by 2024.Advancement medical technology is expected to propel the development of the market.
Technological advancement has played a very vital role the in growth of medical sector. Novel discoveries with regards to treatment, cure research, in the medical industry is expected to boost the market growth. Technological advancement has made medical care very much accessible to common public. Rising research activities in the oncology sector and growing association with research institutes is fuelling the growth.

COVID-19 impact on the market
Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones. These are the effects of recent Covid- 19 pandemic that had a calamitous impact on overall supply chain and logistics across globe bringing economic activity near to stand-still. Public finances have been negatively affected. Despite major developments in pharmaceuticals, the spread of infectious diseases is rising across globe due to globalization, increased trade and travel, urbanisation, reviving pathogens and improper use antibiotics etc. The hospital operational activities witnessed a vast impact on account of disruptions in supply chain of ADC’s across globe. As per American Cancer Society report in 2021, there was 52% decline in diagnosis of breast cancer cases, while 25% reduction in diagnosis of pancreatic cancer during the period of March to April 2020.

Antibody Drug Conjugates Market: Segmentation Analysis

Antibody Drug Conjugates Market based on Drugs Analysis

• Kadcyla
• Adcetris
• Besponsa
• Lumoxiti
• Mylotarg
• Others

Kadcyla was one of the approved drugs by US and Europe for collateral treatment for early patients of HER2-positive breast cancer. The approval of Kadcyla for early-stage treatment is expected to boost the market.Antibody Drug Conjugates Market by Mechanism of Action Analysis

• HER2 Antibodies
• CD30 Antibodies
• OthersAntibody Drug Conjugates Market by Application Analysis

• Lymphoma
• Breast Cancer
• Blood Cancer
• Skin cancer
• Brain Tumor
• Ovary Cancer
• Brain Cancer
• Urothelial & Bladder Cancer
• Other Types of Cancer

Among the application segment the blood cancer segment is anticipated to nurture at a CAGR of 19.4% during the anticipated term. This is attributable to rising incidences of cancerous diseases and approval for ADC’s.Antibody Drug Conjugates Market by Technology Analysis

• InnunoGen technology
• Seattle Genetics technology
• Immunomedics technology
• OthersAntibody Drug Conjugates Market by End User Analysis

• Hospitals

• Specialized Cancer Centers

• Academic Research Institutes

• Biotechnology

• Retail Pharmacies

• Biopharmaceutical Companies

• Others

Antibody Drug Conjugates Market: Geographical ambit

Based on the geographical view, the market occupies regions as North America, Europe, Asia-Pacific, Middle-East and Africa.
North America is dominating the market by 57% share revenue and will continue to do so until the forecasted period. This domination attributes to prevalence of high experienced professionals and better healthcare facilities. Additionally, US FDA was first to approve ACD drugs such as Zynlonta, Blenrep, and Trodelv. Following North America, Europe is the second most country to hold a significant share in the global market.Antibody Drug Conjugates Market: Competitive Landscape

The Antibody Drug conjugates market encompasses several players. There is an aggressive competition. The major players of the market are engaged into intense research and development activities. The key trends of merger and acquisitions in Antibody Drug Conjugates Market are developing. This is the vital strategy adopted by major companies.

Some of the prominent players are AbbVie Inc., ADC Therapeutics, Agensys Inc., Antikor, Astellas Pharma, ADC Therapeutics, Bayer AG, Celldex Therapeutics, Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., Genentech, Gilead Sciences, Inc., GlaxoSmithKline Plc, Heidelberg Pharma, ImmunoGen Inc., Immunomedics Inc., Mersana Therapeutics, Millennium Pharmaceuticals, Oxford Biotherapeutics, Pfizer Inc., Progenics Pharmaceuticals, Roche Holding Ag, Seagen, Inc., Seattle Genetics Inc., Synthon, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., and Others.

Antibody Drug Conjugates Market Forecast Years: 2022-2030
Antibody Drug Conjugates Market Historical Years: 2018-2021
Antibody Drug Conjugates Market 2023: USD 3,198 billion
Antibody Drug Conjugates Market 2030: USD 7475.74 billion
Antibody Drug Conjugates Market CAGR: 12.9%
Key Segments: Drugs, Mechanism of Action, Application, and Region
Key Regions & Countries: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Key Segments: Drugs, Mechanism of Action, Application, Technology, End User
Key Regions & Countries: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Major players profiled: AbbVie Inc., ADC Therapeutics, Agensys Inc., Antikor, Astellas Pharma, ADC Therapeutics, Bayer AG, Celldex Therapeutics, Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., Genentech, Gilead Sciences, Inc., GlaxoSmithKline Plc, Heidelberg Pharma, ImmunoGen Inc., Immunomedics Inc., Mersana Therapeutics, Millennium Pharmaceuticals, Oxford Biotherapeutics, Pfizer Inc., Progenics Pharmaceuticals, Roche Holding Ag, Seagen, Inc., Seattle Genetics Inc., Synthon, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., and Others.